Assetmark, Inc Travere Therapeutics, Inc. Transaction History
Assetmark, Inc
- $47.4 Billion
- Q4 2025
A detailed history of Assetmark, Inc transactions in Travere Therapeutics, Inc. stock. As of the latest transaction made, Assetmark, Inc holds 21,567 shares of TVTX stock, worth $744,061. This represents 0.0% of its overall portfolio holdings.
Number of Shares
21,567Holding current value
$744,061% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding TVTX
# of Institutions
276Shares Held
101MCall Options Held
2.36MPut Options Held
955K-
Janus Henderson Group PLC London, X010.6MShares$366 Million0.12% of portfolio
-
Black Rock Inc. New York, NY7.64MShares$264 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY6.72MShares$232 Million2.47% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.61MShares$228 Million0.0% of portfolio
-
Macquarie Group LTD Australia, C34.98MShares$172 Million0.14% of portfolio
About Travere Therapeutics, Inc.
- Ticker TVTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 64,173,600
- Market Cap $2.21B
- Description
- Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...